Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | UTS2R | Q9UKP6 | 9/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3780660 | 0.86 | MEN1 (0.45) | TAAR1UTS2RGPR84CYP3A4CYP2D6 | |
| SCHEMBL3770440 | 0.84 | MAPK8 (0.44) | UTS2RKCNH2 | |
| SCHEMBL3768759 | 0.83 | UTS2R (0.60) | TAAR1UTS2RCYP3A4CYP2D6KCNH2 | |
| SCHEMBL3768424 | 0.81 | UTS2R (0.44) | UTS2RLRRK2CYP3A4CYP2D6KCNH2 | |
| SCHEMBL3774942 | 0.81 | UTS2R (0.45) | TAAR1UTS2RALDH1A1GPR84LRRK2 | |
| SCHEMBL3775350 | 0.81 | RAB9A (0.53) | TAAR1UTS2RALDH1A1CYP3A4CYP2D6 | |
| SCHEMBL3778794 | 0.81 | NPC1 (0.53) | UTS2RALDH1A1GPR84SMN1; SMN2 | |
| SCHEMBL3771524 | 0.79 | UTS2R (0.45) | TAAR1UTS2RGPR84ADORA3 | |
| SCHEMBL3775019 | 0.78 | UTS2R (0.55) | UTS2RALDH1A1LRRK2CYP3A4CYP2D6 | |
| SCHEMBL3766916 | 0.76 | SMN1; SMN2 (0.45) | UTS2RALDH1A1CYP3A4CYP2D6SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170320870-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2017-11-09 | — | — | US | disclosed |
| US-20170320870-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2017-11-09 | — | — | US | disclosed |
| US-20170320870-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2017-11-09 | — | — | US | disclosed |
| EP-2408772-B1 | COMPOUNDS | MEDICAL RES COUNCIL TECHNOLOGY (GB) | 2015-07-01 | — | — | EP | disclosed |
| US-20100317646-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2010-12-16 | — | — | US | disclosed |
| US-20100317646-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2010-12-16 | — | — | US | disclosed |
| US-20100317646-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170320870-A1 | COMPOUNDS | CBR3, CNR1, HCAR3 | TAAR1 188/4885UTS2R 452/4885ALDH1A1 2980/4885 |
| US-20100317646-A1 | COMPOUNDS | CBR3, CNR1, HCAR3 | TAAR1 196/4885UTS2R 454/4885ALDH1A1 2975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.